Literature DB >> 7586604

Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women?

D J Grant1, M E McMurdo, P A Mole, C R Paterson.   

Abstract

OBJECTIVE: Hyperthyroidism is a risk factor for osteoporosis, but the relative contributions of the episode of hyperthyroidism and thyroxine replacement for subsequent hyperthyroidism remain uncertain. In this study we have measured bone mineral density (BMD) in post-menopausal women with a previous history of hyperthyroidism, comparing those requiring thyroxine therapy with those remaining euthyroid and with an historical local control population.
DESIGN: Cross-sectional study. PATIENTS: One hundred and six post-menopausal women with a previous history of hyperthyroidism. These were divided into four groups: treated with radioiodine, remaining euthyroid (group RU, n = 15); treated with radioiodine, receiving thyroxine for at least 5 years (group RT, n = 46); treated with surgery, remaining euthyroid (group SU, n = 21); treated with surgery, receiving thyroxine for at least 5 years (group ST, n = 24). There were 102 control subjects. MEASUREMENT: Forearm bone mineral density at distal and ultradistal sites as measured by single-photon absorptiometry.
RESULTS: Results were expressed as 'Z-scores' i.e. number of standard deviations from the mean of a 5-year age-band from the local control population. Mean Z-scores at distal and ultradistal sites were as follows: -0.61 and -0.81 in group RU; -0.58 and -0.56 in group RT; -0.27 and -0.30 in group SU; -0.81 and -0.57 in group ST. Patients in groups RU, RT and ST but not SU had significantly lower BMD than controls.
CONCLUSION: Post-menopausal women with previous hyperthyroidism treated with radioiodine have reduced BMD, whether or not receiving thyroxine. They should be targeted for densitometry and protective therapy with oestrogen should be considered. Those treated with surgery appear to be at less risk; this may be because most are diagnosed and treated whilst premenopausal. Thyroxine may have a deleterious effect in this group; longitudinal studies would provide further clarification.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586604     DOI: 10.1111/j.1365-2265.1995.tb02041.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Normalization of cortical bone density in children and adolescents with hyperthyroidism treated with antithyroid medication.

Authors:  N Numbenjapon; G Costin; P Pitukcheewanont
Journal:  Osteoporos Int       Date:  2011-12-21       Impact factor: 4.507

2.  Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.

Authors:  Takafumi Majima; Yasato Komatsu; Kentaro Doi; Chieko Takagi; Michika Shigemoto; Atsushi Fukao; Takeshi Morimoto; Jerry Corners; Kazuwa Nakao
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Bone turnover in hyperthyroidism before and after thyrostatic management.

Authors:  G C Isaia; C Roggia; D Gola; M D Stefano; G Gallone; G Aimo; P Ardissone; M Mussetta
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

4.  Premature hair greying may predict reduced bone mineral density in Graves' disease.

Authors:  A C Leary; G Grealy; T M Higgins; N Buckley; D G Barry; J B Ferriss
Journal:  Ir J Med Sci       Date:  2001 Apr-Jun       Impact factor: 1.568

5.  Intraoperative parathyroid hormone assay in patients with Graves' disease for prediction of postoperative tetany.

Authors:  Taiki Moriyama; Hiroyuki Yamashita; Shiro Noguchi; Yuji Takamatsu; Takahiro Ogawa; Shin Watanabe; Shinya Uchino; Akira Ohshima; Syoji Kuroki; Masao Tanaka
Journal:  World J Surg       Date:  2005-10       Impact factor: 3.282

6.  Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves' disease.

Authors:  Monica A Ercolano; Monica L Drnovsek; Maria C Silva Croome; Monica Moos; Ana M Fuentes; Fanny Viale; Ulla Feldt-Rasmussen; Alicia T Gauna
Journal:  Thyroid Res       Date:  2013-09-11

Review 7.  Bone disease in thyrotoxicosis.

Authors:  P Amaresh Reddy; C V Harinarayan; Alok Sachan; V Suresh; G Rajagopal
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

8.  Metabolic and clinical consequences of hyperthyroidism on bone density.

Authors:  Jagoda Gorka; Regina M Taylor-Gjevre; Terra Arnason
Journal:  Int J Endocrinol       Date:  2013-07-22       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.